Patents by Inventor John Dresios
John Dresios has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230183299Abstract: The present disclosure provides materials and methods for cell-free expression of epitopes for immunotherapy applications. In particular, the present disclosure provides materials and methods for expressing concatenated epitopes using a cell-free protein synthesis platform for high throughput, large scale, and unbiased epitope screening and the generation of multi-epitope vaccines.Type: ApplicationFiled: February 22, 2023Publication date: June 15, 2023Applicant: Leidos, Inc.Inventors: Stephen A. Chappell, Vincent P. Mauro, John Dresios
-
Patent number: 11639514Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.Type: GrantFiled: April 10, 2020Date of Patent: May 2, 2023Assignee: Leidos, Inc.Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
-
Patent number: 11608363Abstract: The present disclosure provides materials and methods for cell-free expression of epitopes for immunotherapy applications. In particular, the present disclosure provides materials and methods for expressing concatenated epitopes using a cell-free protein synthesis platform for high throughput, large scale, and unbiased epitope screening and the generation of multi-epitope vaccines.Type: GrantFiled: July 1, 2019Date of Patent: March 21, 2023Assignee: Leidos, IncInventors: Stephen A. Chappell, Vincent P. Mauro, John Dresios
-
Publication number: 20200277643Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.Type: ApplicationFiled: April 10, 2020Publication date: September 3, 2020Applicant: Leidos, IncInventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
-
Patent number: 10662457Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.Type: GrantFiled: February 16, 2018Date of Patent: May 26, 2020Assignee: Leidos, Inc.Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
-
Publication number: 20200155966Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.Type: ApplicationFiled: February 16, 2018Publication date: May 21, 2020Applicant: Leidos, Inc.Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
-
Publication number: 20200010512Abstract: The present disclosure provides materials and methods for cell-free expression of epitopes for immunotherapy applications. In particular, the present disclosure provides materials and methods for expressing concatenated epitopes using a cell-free protein synthesis platform for high throughput, large scale, and unbiased epitope screening and the generation of multi-epitope vaccines.Type: ApplicationFiled: July 1, 2019Publication date: January 9, 2020Applicant: Leidos, Inc.Inventors: Stephen A. Chappell, Vincent P. Mauro, John Dresios
-
Patent number: 10101339Abstract: The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.Type: GrantFiled: June 24, 2016Date of Patent: October 16, 2018Assignee: Leidos, Inc.Inventors: John Dresios, Richard Griffey
-
Patent number: 9908064Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.Type: GrantFiled: January 29, 2016Date of Patent: March 6, 2018Assignee: Leidos, Inc.Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
-
Publication number: 20170089922Abstract: The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.Type: ApplicationFiled: June 24, 2016Publication date: March 30, 2017Applicant: Leidos, Inc.Inventors: John Dresios, Richard Griffey
-
Publication number: 20160230203Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.Type: ApplicationFiled: January 29, 2016Publication date: August 11, 2016Applicant: Leidos, Inc.Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
-
Patent number: 9387253Abstract: The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.Type: GrantFiled: November 6, 2015Date of Patent: July 12, 2016Assignee: Leidos, Inc.Inventors: John Dresios, Richard Griffey
-
Publication number: 20160106850Abstract: The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.Type: ApplicationFiled: November 6, 2015Publication date: April 21, 2016Applicant: Leidos, Inc.Inventors: John Dresios, Richard Griffey
-
Patent number: 9238068Abstract: The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.Type: GrantFiled: January 17, 2014Date of Patent: January 19, 2016Assignee: Leidos, Inc.Inventors: John Dresios, Richard Griffey
-
Patent number: 9180190Abstract: The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.Type: GrantFiled: January 17, 2014Date of Patent: November 10, 2015Assignee: Leidos, Inc.Inventors: John Dresios, Richard Griffey
-
Publication number: 20140134192Abstract: The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.Type: ApplicationFiled: January 17, 2014Publication date: May 15, 2014Applicant: Leidos, Inc.Inventors: John Dresios, Richard Griffey
-
Patent number: 8663932Abstract: The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.Type: GrantFiled: December 21, 2011Date of Patent: March 4, 2014Assignee: Leidos, Inc.Inventors: John Dresios, Richard Griffey
-
Publication number: 20120156283Abstract: The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.Type: ApplicationFiled: December 21, 2011Publication date: June 21, 2012Applicant: Science Applications International CorporationInventors: John Dresios, Richard Griffey
-
Patent number: RE46584Abstract: The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.Type: GrantFiled: January 26, 2016Date of Patent: October 24, 2017Assignee: Leidos, Inc.Inventors: John Dresios, Richard Holmes Griffey